NeoStem To Present At Multiple November Conferences

NEW YORK, Oct. 31, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, announced today that the Company and its subsidiary, Progenitor Cell Therapy ("PCT"), will present at multiple upcoming conferences in November.

BIO-Europe 2013-19 th Annual International Partnering Conference
  • Date and Time: Monday, November 4, 2013, 2:45 PM CEST
  • Venue: Messe Wien Exhibition and Congress Center, Vienna, Austria
  • Session: "What is the role of large pharma in developing advanced therapy medicinal products—are they essential or not?"
  • Moderator: Robert A. Preti, Ph.D., Chief Scientific Officer, NeoStem, and President, PCT

Landmark Venture Forum – Investing for Cures 2013
  • Date and Time: Wednesday, November 6, 2013, 2:00 PM EST
  • Venue: Union League Club, New York, New York
  • Session: Company Presentation
  • Speaker: Robin L. Smith, MD, MBA, Chairman and CEO, NeoStem

American Heart Association Annual Scientific Sessions 2013
  • Venue: Dallas Convention Center, Dallas, Texas
  • Date and Time: Monday, November 18, 2013, 9:00 AM CST
  • Session 1: "Clinical Science Special Reports"
  • Panelist: Douglas W. Losordo, MD, Chief Medical Officer, NeoStem
  • Date and Time: Tuesday, November 19, 2013, 9:00 AM CST
  • Session 2: "George E. Brown Memorial Lecture and Adult Stem Cells: Cardiac Homeostasis and Repair"
  • Moderator: Douglas W. Losordo, MD, Chief Medical Officer, NeoStem

11 th Annual Commercial Translation of Regenerative Medicine 2013
  • Date and Time: Tuesday, November 26, 4:20 PM BST
  • Venue: Charing Cross Hotel, London, United Kingdom
  • Session: "Case Study - Capturing and Preparing for Licensing and Acquisition"
  • Speaker: Robin L. Smith, MD, MBA, Chairman and CEO, NeoStem

London Regenerative Medicine Network
  • Date and Time: Tuesday, November 26, 6:35 PM BST
  • Venue: University College London, Bloomsbury campus, London, United Kingdom
  • Session: Company Presentation
  • Speaker: Robin L. Smith, MD, MBA, Chairman and CEO, NeoStem

About NeoStem, Inc.

NeoStem, Inc. is a leader in the emerging cellular therapy industry. Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with capabilities for cost effective in-house product development and immediate revenue and cash flow generation.

If you liked this article you might like

Neostem (NBS) Stock Declines After Pricing Secondary Public Offering

3 Breakout Stocks Under $10 for Your Trading Radar

Insider Trading Alert - UGI, NBS And MACK Traded By Insiders

Neostem (NBS): Today's Weak On High Volume Stock

NeoStem (NBS) Stock Plummets Today on Disappointing Cardiac Stem-Cell Therapy Data